32
Participants
Start Date
October 28, 2015
Primary Completion Date
June 15, 2018
Study Completion Date
June 15, 2018
Remestemcel-L
No intervention was given in Study MSB-GVHD002 (NCT02652130). It was a safety follow-up trial of remestemcel-L-treated participants from Study MSB-GVHD001.
Columbia University Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
The Children's Hospital at Montefiore, New York
Alfred I. duPont Hospital for Children of the Nemours Foundation, Wilmington
Virginia Commonwealth University, Richmond
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Miami Children's Research Institute, Miami
University of Mississippi Medical Center, Jackson
Children's Hospital of Michigan, Detroit
Medical College of Wisconsin, Milwaukee
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington University, St Louis
Texas Transplant Institute, San Antonio
Children's Hospital Colorado Center for Cancer/Blood Disorders, Aurora
Children's Hospital Los Angeles, Los Angeles
CHOC Children's Hospital of Orange County, Orange
UCSF Benioff Children's Hospital, San Francisco
Oregon Health & Science University, Portland
Fred Hutchinson Cancer Center, Seattle
Lead Sponsor
Quintiles, Inc.
INDUSTRY
Mesoblast, Inc.
INDUSTRY